Skip to main content

Cardiovascular Diseases

Cardiovascular Diseases group is a translational research group within the Cardiology Department of Vall d’Hebron Hospital that performs laboratory, clinical and epidemiological research. In the CIBERCV network we are within the topic of descriptor 2 “Arterial disease, thrombosis and myocardial ischemia-reperfusion injury”. Our contributions in these topics address the following lines: 

  • Myocardial ischemia-reperfusion injury (i.e. mechanisms of endogenous cardioprotection, ischemic conditioning and remodeling), 
  • Coronary artery disease (i.e. genetic factors involved in coronary artery disease, determinants of thrombotic complications and prognosis), 
  • Aortic diseases (i.e. determinants of aorta dilatation, aortic biomechanics abnormalities in Marfan´s syndrome, and new imaging methods), 
  • Congenital/familiar heart diseases (i.e. genetic determinants and prognosis factors). 

In the CIBERESP network, our group is interested in the study of effectiveness/cost-effectiveness of cardiovascular interventions, health outcome research and methods in clinical research. The group has 19 principal investigators, 32 active projects and clinical trial and has been done 142 publications in 2020.

Team

Amarilis Sofia Baekelandt

Amarilis Sofia Baekelandt

Research technician
Cardiovascular Diseases
Read more
Anna Martí Boltaina

Anna Martí Boltaina

Research technician
Cardiovascular Diseases
Read more
Anna Vidal Romero

Anna Vidal Romero

Junior researcher
Cardiovascular Diseases
Read more
Blanca Gordon Ramírez

Blanca Gordon Ramírez

Main researcher
Cardiovascular Diseases
Read more
Carlota María Vigil-Escalera López

Carlota María Vigil-Escalera López

Research technician
Cardiovascular Diseases
Read more
Eduardo Ródenas Alesina

Eduardo Ródenas Alesina

Predoctoral researcher
Cardiovascular Diseases
Read more
Amarilis Sofia Baekelandt

Amarilis Sofia Baekelandt

Research technician
Cardiovascular Diseases
Read more
Anna Martí Boltaina

Anna Martí Boltaina

Research technician
Cardiovascular Diseases
Read more
Anna Vidal Romero

Anna Vidal Romero

Junior researcher
Cardiovascular Diseases
Read more
Blanca Gordon Ramírez

Blanca Gordon Ramírez

Main researcher
Cardiovascular Diseases
Read more
Carlota María Vigil-Escalera López

Carlota María Vigil-Escalera López

Research technician
Cardiovascular Diseases
Read more
Eduardo Ródenas Alesina

Eduardo Ródenas Alesina

Predoctoral researcher
Cardiovascular Diseases
Read more

Projects

Inhibición del intercanviador sodio/calcio mitocondrial, NCLX, como estrategia terapéutica para reducir el daño miocárdico por isquemia-reperfusión durante el infarto de miocardio.

IP: Antonio Rodríguez Sinovas
Collaborators: Laia Yañez Bisbe, Remedios Rios Barrera, Laura Rubio Unguetti, Gino Freddy Sena Ganse
Funding agency: Instituto de Salud Carlos III
Funding: 127500
Reference: PI23/00260
Duration: 01/01/2024 - 31/12/2027

IMPROVE: Framework to IMPROVE the Integration of Patient Generated Health Data to Facilitate Value Based Healthcare

IP: Bruno Garcia del Blanco
Collaborators: -
Funding agency: EUROPEAN COMMISSION
Funding: 222818.75
Reference: IMPROVE_IHI-CALL3-2023
Duration: 01/12/2023 - 30/11/2028

Toxicitat cardiovascular en el càncer de mama HER 2-positiu precoç: desde l'avaluació del risc fins a la prevenció

IP: Ignacio Ferreira González
Collaborators: José Antonio Barrabés Riu, Cristina Saura Manich, José Raul Herance Camacho, Gerard Oristrell Santamaria, Javier Limeres Freire, Raul Aguilar Lopez, Filipa Xavier De Carvalho Negrao Valente, Toxicitat cardiovascular en el càncer de mama HER 2-positiu precoç: desde l'avaluació del risc fins a la prevenció, Nuria Coma Auli
Funding agency: Fundació La Marató de TV3
Funding: 198125
Reference: 202311-10
Duration: 11/03/2024 - 10/03/2027

AI4HF: Trustworthy Artificial Intelligence for Personalised Risk Assessment in Chronic Heart Failure

IP: Jose Fernando Rodríguez Palomares
Collaborators: Ignacio Ferreira González, Pere López Gutierrez, AI4HF: Trustworthy Artificial Intelligence for Personalised Risk Assessment in Chronic Heart Failure, AI4HF: Trustworthy Artificial Intelligence for Personalised Risk Assessment in Chronic Heart Failure, Gisela Teixido i Tura, Eduardo Ródenas Alesina, Alicia Fresno González, Toni Soriano Colomé, Garazi Urio Garmendia, Lydia Dux-Santoy Hurtado, Andrea Guala
Funding agency: EUROPEAN COMMISSION
Funding: 293125
Reference: AI4HF_HE-HLTH-STAYHLTH2022
Duration: 01/06/2023 - 31/05/2027

Blog

News

Women have a mortality rate of 21% during the 30 days following surgery, compared with 11% in men, a difference that remains after taking patients’ clinical characteristics into account.

The families of the professionals had the opportunity to visit the facilities and discover how we work at the institution.

The study, with the participation of VHIR, will analyse the physiological response of the human body thanks to data collected by smartwatches and wearable devices.

Rates

Icona fitxers

Echocardiography Rates

PDF 0.66 MB

Icona fitxers

Hemodynamics Rates

PDF 0.47 MB